IR presentations by 20 ventures and startups with promising technologies in all fields of pharmaceuticals and biotechnology
The Korea New Drug Development Research Association (Chairman Hong Seong-han, hereinafter referred to as the New Drug Association) is affiliated with the Pharmaceutical and Bio Business Development Research Association (Chairman Lee Jae-hyun, hereinafter referred to as K-BD Group), an organization of domestic industry, academia, research, venture and startup business development experts. The '2022 1st Promising Bio Venture and Startup Investment Forum' was held at KINTEX in Ilsan over two days from Wednesday, June 15th to Thursday, June 16th, attracting industry, academia, research, and government officials from the biohealth industry. It was announced that it was successfully completed with about 100 people in attendance.
This investment forum, hosted by the New Drug Association and jointly organized by K-BD Group and Ajou Advanced Medical Bio Research Institute, was held as part of promoting open innovation in the domestic biohealth industry and invited investment institutions such as domestic pharmaceutical and biotech companies and venture capital to identify promising bioventures and biotechnology companies. It was designed to provide opportunities for win-win cooperation and information exchange, including discovery of excellent items/platforms, investment, and M&A, through networking with startup companies.
In addition, Nforyu Technology Holdings Co., Ltd., Daekyung Technology Holdings Co., Ltd., Sogang University Industry-Academic Cooperation Foundation, Sookmyung Women's University Technology Holdings Co., Ltd., Ewha Womans University Technology Holdings Co., Ltd., Ajou University Technology Holdings Co., Ltd., SWP Co., Ltd., Hongneung Gangso Special Zone Project Group, Asan Medical Center in Seoul A total of 9 institutions/universities, including the Bio Core Facility Center, participated as cooperative organizations.
This investment, which began with greetings from K-BD Group Research Chairman Lee Jae-hyun and Aju Advanced Medical Bio Research Institute Chairman Kim Soo-dong, includes One Cure Gen, Curs Bio, Repure Healthcare, PRGS&Tech, Ludacure, GH Pharm, Medi Helpline, 20 companies participated and held, including Trial Informatics, Unt Bio, Cosmos Whale, Kaiser Bio, Korea CR-O, Iretech Korea, Heaven Bio, Silicopharm, I'm System, Goodbing Center, Ewire Liner, F.in Company, and Phyto Map. An IR presentation was made about the existing research and development pipeline and partnership and cooperation plans.
An official from the New Drug Association said, “Recently, in order to overcome the limitations of closed research and development (R&D) in which domestic and foreign pharmaceutical companies develop new drugs with their own capabilities, we are trying to dominate promising technologies through various cooperation measures such as joint research, technology transfer, investment, and M&A. “We are expanding open innovation,” he said.
He continued, “By holding investment forums, R&D-centered blue-chip pharmaceutical and bio company IR (IPIR), and Interbiz Bio Partnering & Investment Forum, we are minimizing risks in the R&D and commercialization process of venture and startup companies and pharmaceutical and bio companies ( “We will do our best to promote the creation of a healthy open innovation ecosystem so that investment organizations such as large corporations, mid-sized companies, small and medium-sized enterprises (SMEs, etc.) and venture capitals can achieve mutual win-win through securing promising technologies, cooperation, and investment.”
Meanwhile, as part of promoting open innovation in the domestic biohealth industry, K-BD Group provides a networking opportunity for companies such as domestic pharmaceutical and bio companies and investment institutions such as venture capital with bio ventures and startup companies that own promising technologies or platforms. In order to provide opportunities for win-win cooperation and information exchange, such as discovering excellent technologies, investing, and M&A, we started operating an investment forum in 2019 and are holding it twice a year.
Reporter Noh Young-hee nyh2152@medifonews.co
Registered 2022-06-16 14:35:37
Comments